These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32872144)

  • 1. Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies.
    Huss A; Senel M; Abdelhak A; Mayer B; Kassubek J; Ludolph AC; Otto M; Tumani H
    Biomedicines; 2020 Aug; 8(9):. PubMed ID: 32872144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
    Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Jun; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis.
    Abdelhak A; Benkert P; Schaedelin S; Boscardin WJ; Cordano C; Oechtering J; Ananth K; Granziera C; Melie-Garcia L; Montes SC; Beaudry-Richard A; Achtnichts L; Oertel FC; Lalive PH; Leppert D; Müller S; Henry RG; Pot C; Matthias A; Salmen A; Oksenberg JR; Disanto G; Zecca C; D'Souza M; Du Pasquier R; Bridel C; Gobbi C; Kappos L; Hauser SL; Cree BAC; Kuhle J; Green AJ;
    JAMA Neurol; 2023 Dec; 80(12):1317-1325. PubMed ID: 37930670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis.
    Sandgren S; Novakova L; Nordin A; Axelsson M; Malmeström C; Zetterberg H; Lycke J
    Front Neurol; 2023; 14():1265354. PubMed ID: 37808497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
    Gil-Perotin S; Castillo-Villalba J; Cubas-Nuñez L; Gasque R; Hervas D; Gomez-Mateu J; Alcala C; Perez-Miralles F; Gascon F; Dominguez JA; Casanova B
    Front Neurol; 2019; 10():1008. PubMed ID: 31608004
    [No Abstract]   [Full Text] [Related]  

  • 9. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
    Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H
    Front Neurol; 2020; 11():608. PubMed ID: 32765393
    [No Abstract]   [Full Text] [Related]  

  • 10. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study.
    Kızılay T; Akbayir E; Erol R; Demir AS; Özkan Yaşargün D; Yilmaz V; Tuzun E; Turkoglu R
    Eur Neurol; 2024 Jun; ():1-8. PubMed ID: 38754397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
    Piehl F; Kockum I; Khademi M; Blennow K; Lycke J; Zetterberg H; Olsson T
    Mult Scler; 2018 Jul; 24(8):1046-1054. PubMed ID: 28627962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis.
    Røsjø E; Lindstrøm JC; Holmøy T; Myhr KM; Varhaug KN; Torkildsen Ø
    Front Neurol; 2020; 11():329. PubMed ID: 32425877
    [No Abstract]   [Full Text] [Related]  

  • 14. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
    Kuhle J; Kropshofer H; Haering DA; Kundu U; Meinert R; Barro C; Dahlke F; Tomic D; Leppert D; Kappos L
    Neurology; 2019 Mar; 92(10):e1007-e1015. PubMed ID: 30737333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High or increasing serum NfL is predictive of impending multiple sclerosis relapses.
    Thebault S; Reaume M; Marrie RA; Marriott JJ; Furlan R; Laroni A; Booth RA; Uccelli A; Freedman MS
    Mult Scler Relat Disord; 2022 Mar; 59():103535. PubMed ID: 35078125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
    Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
    Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
    de Flon P; Gunnarsson M; Laurell K; Söderström L; Birgander R; Lindqvist T; Krauss W; Dring A; Bergman J; Sundström P; Svenningsson A
    Neurology; 2016 Jul; 87(2):141-7. PubMed ID: 27316241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum GFAP as a biomarker for disease severity in multiple sclerosis.
    Abdelhak A; Huss A; Kassubek J; Tumani H; Otto M
    Sci Rep; 2018 Oct; 8(1):14798. PubMed ID: 30287870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to neurofilament light as potential biomarkers in multiple sclerosis.
    Puentes F; Benkert P; Amor S; Kuhle J; Giovannoni G
    BMJ Neurol Open; 2021; 3(2):e000192. PubMed ID: 34786556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.